Thursday, October 28, 2004

New bacterial meningitis vaccine

It looks like we are getting another vaccine
that fails a cost-benefit analysis. The NY Times says:
The price of the new vaccine will most likely be $80 a dose. Vaccinating all 40 million people from age 11 to 20, as some experts have suggested, would cost the government $3.5 billion next year. That is more than $1 million a life spared, far more than health officials are normally willing to spend.
This NY Times article explains that vaccines are really a growth business, in spite of all the bad press about the flu vaccine.

No comments: